Multiple Myeloma

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Novel therapeutics, including thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade), have revolutionized the treatment of multiple myeloma.

The FDA has deemed subcutaneous injection as a safe and valid method of delivering the drug bortezomib in patients with multiple myeloma.

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

The availability of effective novel agents for the treatment of multiple myeloma - including thalidomide, lenalidomide, and bortezomib - has validated the concept of maintenance therapy in myeloma patients.

Dr. James Berenson from the Institute for Myeloma & Bone Cancer Research Discusses the Carfilzomib Toxicity Profile

Current treatments revolutionized multiple myeloma but combinations and novel approaches in development promise to make even greater strides in treating this disease.

Dr. James Berenson from the Institute for Myeloma and Bone Cancer Research Discusses the Proteasome Inhibitor Carfilzomib

In 2001, Doug Rickert, a 46-year-old industrial management consultant and married father of 3, heard the life-altering words, "softball-sized tumor pressing against your spinal canal."

You'd never know that Rogers has had multiple myeloma for almost 11 years -- and that's just the way he likes it.

Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.

A look at dramatic changes in the landscape of multiple myeloma that have occurred over the past decade and new developments in the context of stem cell transplantation in non-Hodgkin lymphoma.

Every decade during the past 50 years, treatment for multiple myeloma has taken a leap forward.

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

Researchers have sequenced 38 tumor genomes from patients with multiple myeloma (MM), comparing them with normal DNA.

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, discusses ongoing myeloma clinical trials in the spring of 2011.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.